Abstract:Abstract Background: Resisting cell death is one of the hallmarks of cancer. Necroptosis is a form of non-caspase dependent necrotic cell death mediated by receptor-interacting protein kinase-1/3 (RIP1/3), which represents another mode of programmed cell death besides apoptosis. Growing evidence supports that RIP3 has emerged as a critical regulator of necroptosis and can be activated by several stimuli to trigger necroptotic cell death in a RIP1-independent manner. RIP3 also acts as an energy metabolism regulator associated with switching cell death from apoptosis to necroptosis. Natural products provide a unique source for the discovery of innovative leading compounds and drugs, which exhibits promising anticancer activities through inducing cell death and enhancing chemotherapeutic sensitivity. Trichothecin (TCN) is a sesquiterpenoid originating from an endophytic fungus of the herbal plant Maytenus hookeri Loes and shows potent anti-tumor bioactivity. However, the underlying mechanism is not fully understood.Methods: Cell permeability assay and transmission electron microscopy were applied to identify the death pattern induced by TCN in apoptotic-resistant cancer cells. We used Seahorse extracellular flux analyzer to examine the cellular oxygen consumption rate (OCR) and flow cytometry to detect mitochondrial reactive oxygen species (ROS) content. Xenograft animal experiment was performed to assess the effect of TCN synergized with cisplatin to enhance chemotherapeutic sensitivity of tumor cells. Results: Our current findings revealed that RIP3 mediated TCN-induced necroptosis through activating mitochondria energy metabolism and ROS production in apoptotic-resistant cancer cells. RIP3 might be involved in sensitizing tumor cells to chemotherapy induced by TCN. Conclusions: Activating RIP3 to induce necroptosis through reprogramming mitochondrial energy metabolism and ROS production contributes to the anti-tumor activity of TCN. Moreover, TCN could be exploited for therapeutic gain through up-regulating RIP3 to sensitize cancer chemotherapy.

Cisplatin-induced Necroptosis in TNFα Dependent and Independent Pathways.

A Role for Tubular Necroptosis in Cisplatin-Induced AKI.

Receptor Interacting Protein Kinase 3 Promotes Cisplatin-Induced Necroptosis in Apoptosis-Resistant HepG2/DDP Cells.

Receptor Interactive Protein Kinase 3 Promotes Cisplatin-triggered Necrosis in Apoptosis-Resistant Esophageal Squamous Cell Carcinoma Cells.

RIPK1 inhibitor Cpd-71 attenuates renal dysfunction in cisplatin-treated mice via attenuating necroptosis, inflammation and oxidative stress.

Cisplatin Induces Apoptosis of Hepatocellular Carcinoma LM3 Cells Via Down-Regulation of XIAP.

MLKL-PITPα signaling-mediated necroptosis contributes to cisplatin-triggered cell death in lung cancer A549 cells.

Cisplatin-induced Apoptosis in P53-Deficient Renal Cells Via the Intrinsic Mitochondrial Pathway

Necrostatin-1 Attenuates Cisplatin-Induced Nephrotoxicity Through Suppression of Apoptosis and Oxidative Stress and Retains Klotho Expression

Cisplatin-induced Non-Apoptotic Death of Pancreatic Cancer Cells Requires Mitochondrial Cyclophilin-D-p53 Signaling.

RIP3 mediates TCN-induced necroptosis through activating mitochondrial metabolism and ROS production in apoptosis-resistant cancer cells

Critical role of CD40-mediated autocrine tumor necrosis factor-alpha in potentiation of cisplatin-induced cytotoxicity in cancer cells.

Cisplatin Induces Platelet Apoptosis Through the ERK Signaling Pathway

Down-regulation of RIP3 Potentiates Cisplatin Chemoresistance by Triggering HSP90-ERK Pathway Mediated DNA Repair in Esophageal Squamous Cell Carcinoma.

Retaining MKP1 Expression and Attenuating JNK-mediated Apoptosis by RIP1 for Cisplatin Resistance Through Mir-940 Inhibition

The multitargeted kinase inhibitor KW-2449 ameliorates cisplatin-induced nephrotoxicity by targeting RIPK1-mediated necroptosis

Zinc finger domain of p62/SQSTM1 is involved in the necroptosis of human cisplatin‑resistant ovarian cancer cells treated with sulfasalazine

Cisplatin-mediated c-myc overexpression and cytochrome c (cyt c) release result in the up-regulation of the death receptors DR4 and DR5 and the activation of caspase 3 and caspase 9, likely responsible for the TRAIL-sensitizing effect of cisplatin

RIP3 Mediates TCN-induced Necroptosis Through Activating Mitochondrial Metabolism and ROS Production in Chemotherapy-Resistant Cancers.

Differential Roles of RIPK1 and RIPK3 in TNF-induced Necroptosis and Chemotherapeutic Agent-Induced Cell Death.

P2X7 receptor deficiency attenuates cisplatin-induced kidney injury via inhibiting NLRP3 inflammasome activation